Hulio, Biosimilar of Humira, Wins FDA Approval for JIA, But Not Available Until 2023
News
The U.S. Food and Drug Administration (FDA) has approved Hulio, a biosimilar of Humira (adalimumab), for the treatment of juvenile idiopathic arthritis (JIA) in individuals ages 4 and older. However, the biosimilar will ... Read more